Navigation Links
AFFiRiS Begins Development of a Parkinson's Vaccine
Date:12/11/2008

VIENNA, Austria, December 11 /PRNewswire/ -- AFFiRiS has started pre-clinical development of a Parkinson's vaccine. The vaccine, known as PD01, can be used to target a specific protein that is closely associated with the causes of this degenerative neurological disease. Excellent product candidates from discovery studies have prompted the company to file a patent application and proceed immediately with development. Similarly positive results from external assessments impelled the Austrian Research Promotion Agency (FFG) to provide considerable financial funding for the project. The vaccine is based on the company's AFFITOME technology, which, among other things, has already been used to develop two Alzheimer's vaccines, which are currently both in phase I clinical testing.

AFFiRiS, based in Vienna, Austria, today announced the start of the pre-clinical development of its first Parkinson's vaccine PD01. The vaccine will be investigated for efficacy ("proof of concept") in Parkinson models. On successful conclusion of this preclinical evaluation, initial clinical testing could start in 2010/11. The Parkinson's vaccine specifically targets the alpha-synuclein (alpha-syn) protein, which is considered to be a key contributory element in Parkinson's disease.

Although all details of the disease are not yet fully understood, there is clear scientific evidence that the concentration and enrichment of alpha-syn in the brain are contributing factors in the progression of Parkinson's disease. Therefore, reducing the alpha-syn burden in the brain should have a positive impact on the course of the disease - a hypothesis that was recently confirmed by the results of U.S. researchers working on animal models.

The Parkinson's vaccine from AFFiRiS has been developed to delivery efficacy in combination with an excellent safety profile, as Dr. Walter Schmidt, CEO of AFFiRiS, explains: "Alpha-syn is an attractive target for treating the cause - not just the symptoms - of Parkinson's. However, it is important to bear in mind that alpha-syn is a human protein belonging to a family of proteins with very similar structures like e.g. beta-syn, an essential neuroprotective factor. Therefore, treatment to reduce alpha-syn must not lead to the reduction of related proteins, such as beta-syn. Our AFFITOME technology enables us to develop vaccines that induce antibody specifically targeting alpha-syn only."

Frank Mattner, Chief Scientific Officer at AFFiRiS, adds: "The great potential offered by our AFFITOME technology has been confirmed by external experts, who appraised our development of a Parkinson's vaccine for the Austrian Research Promotion Agency (FFG). Their assessment prompted the FFG to provide considerable financial support for this project."

The AFFITOME technology from AFFiRiS provides a means of targeting very specific structures of human rogue proteins with patented product candidates. AFFiRiS has already succeeded in developing two vaccines and a hemodialysis program for the treatment of Alzheimer's. These therapies only target specific structures found on harmful fragments of beta-amyloid, which is said to be responsible for Alzheimer's. Both Alzheimer's vaccines are currently being trialled on Alzheimer patients. In October, a licence option agreement worth up to EUR 430 million was concluded with GlaxoSmithKline Biologicals for their further clinical development market launch and sales.

About AFFiRiS GmbH (as at December 2008):

AFFiRiS GmbH develops peptide-based vaccines for the treatment of Alzheimer's disease, atherosclerosis and other serious diseases. The company has established its AFFITOME platform technology. It employs 35 highly qualified members of staff on 1,800sqm of rented laboratory facilities at the Campus Vienna Biocenter (http://www.affiris.com). AFFITOME and AFFITOPE are registered trademarks of AFFiRiS GmbH.

About MIG-Fonds:

The participation of MIG Verwaltungs AG in Affiris GmbH represents the continuation of a tried-and-tested approach. Investment is only made in selected companies in Germany and Austria after their viability has been thoroughly audited. Their innovative, high-potential products and the entrepreneurial skills of their management teams are both key. MIG Verwaltungs AG is supported by Alfred Wieder AG. This specialist in venture capital is experienced in the sale of holdings and is therefore the first point of contact for any potential investors.

    Contact for Affiris GmbH:
    Mag. Agnes Meyer
    Campus Vienna Biocenter
    1030 Vienna
    T +43-1-798-15-75-10
    E Agnes.Meyer@affiris.com

    Copy Editing & Distribution:
    PR&D - Public Relations for Research & Education
    Campus Vienna Biocenter 2
    1030 Vienna
    T +43-1-505-70-44
    E contact@prd.at
    Whttp://www.prd.at


'/>"/>
SOURCE AFFiRiS GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. AFFiRiS: Milestone Reached in Clinical Trial of Alzheimers Vaccine
2. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
3. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
4. Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
5. Patient Recruitment Begins in India for Phase 3 Diabetes Trial
6. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
7. Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins
8. Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
9. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
10. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Südkorea, 23. Februar 2017 LG Innotek ... Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls ... Strahlung im Bereich zwischen 200 und 280 nm und eignet ... Bakterien, indem es ihre DNA zerstört. Das Produkt von ... ...
(Date:2/23/2017)... Feb. 23, 2017 ITL Limited, ( ASX: ITD ), ... for the half year ended 31 December 2016 compared with the ... presentation can be viewed here . Highlights ... $1.04m; up 104%) Earnings per share of 2.2 ... of $17.5m (Dec 2015: $15.7m; up 11%) Profit ...
(Date:2/23/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - 2016, provides ... research answers the following questions: What are ... they positioned in the Global Menopause market? What are ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... 2017 , ... Occupational pesticide exposure is linked to an ... according to a study released today at the 1st Pan American Parkinson’s and ... pesticides and incidence of sporadic PD through occupational exposure. This latest study, led ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... replacement options at his office, Antoine Dental Center. Currently, patients can get single ... restrictions may apply, but patients can learn more about these offers by contacting ...
(Date:2/24/2017)... , ... February 24, 2017 , ... An in-depth computational ... the University of Pittsburgh points to eight genes that may explain why susceptibility to ... to the results of a study published today in the journal npj Schizophrenia. ...
(Date:2/24/2017)... ... , ... In the Health Care IT campaign, Robert Herjavec discusses health IT ... you will be attacked, but when.” However, he and many others involved highlight a ... Improvements in auditing and monitoring have taken security in health care a very long ...
(Date:2/24/2017)... ... , ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” ... paramedic experiences. Schanssema describes the tragedies he saw, as well as his struggles with ... Schanssema, initially unsure of the career path he wanted to take, found fulfillment in ...
Breaking Medicine News(10 mins):